Thinh Nguyen Duc
Senior Director, Business Development at Regeneron Pharmaceuticals, Inc.
- Role
- Senior Director of Business Development at Regeneron
- Location
- New York, NY, US
- LinkedIn followers
- 500 followers
About Thinh Nguyen Duc
BD lead. End-to-end leadership on high-value transactions, owning the entire \"soups to nuts\" process from ideation, search and eval, term sheet negotiation to the final contract signature. Announced transactions-$2.1B co-development deal with Telix Pharmaceuticals.$40M upfront,$2.1B in milestone payments (2026)-$275M co-development deal with Tessera Therapeutics (2025)-$100M research collaboration with Mammoth Biosciences (2024)- Global (LATAM, CEE, Australia/NZ) commercial distribution for Libtayo (anti-PD1)(undisclosed upfront, financials)(2023)-$1.1B Acquisition of global right to Libtayo (anti-PD1).$900M upfront,$200M in milestone payments (2022)- Investment (undisclosed financials) and development agreement with Ultima Genomics (2022)-$3B repurchase of Regeneron’s stock (2021)-$11.7B repurchase and secondary offering of 23M shares of Regeneron stock held by Sanofi (2020)- Inaugural $1B repurchase of Regeneron’s stock (2019)-$230M WW development and commercialization agreement to out-license two clinical-stage assets and two preclinical assets in oncology from Vertex to Merck KGaA (2017)
Experience
Senior Director of Business Development
Jan 2025 — Present
BD lead driving the full deal lifecycle—from initial search and evaluation through final execution—with deep expertise in Genetic Medicine and antibody platform technologies.I provide end-to-end leadership on high-value transactions, owning the entire \"soups to nuts\" process from term sheet negotiation to the final signature. •Announced deals-$2.1B co-development with Telix Pharmaceuticals -$275M co-development with Tessera Therapeutics-$100M research collaboration with Mammoth Biosciences-$1.1B purchase of global right to Libtayo from SNY- Distribution agreements (full agency) in LATAM, CEE, Australia, New Zealand, South Korea and Taiwan for Libtayo (undisclosed upfront and financials.)- Equity investment in Ultima Genomics (undisclosed financials.)
Education
Cornell University
Doctor of Philosophy (Ph.D.), Chemical Biology
2010 — 2015
Stanford University
Bachelor of Science in Biology (Honors)
2005 — 2009
Stanford University
Master of Science - MS, Management Science & Engineering
2009 — 2010
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.